WGS Earnings & Financial Statements
GeneDx Holdings Corp.
$69.46
+$1.73(+2.55%)
40
Overall
40
Value
27
Tech
55
Quality
Market Cap
$2.02B
Volume
26.03K
52W Range
$27.59 - $105.18
Target Price
$91.44
WGS earnings and financial statements: GeneDx Holdings Corp.'s income statement, balance sheet and cash flow statement, annual and quarterly.
WGS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $427.54M | $305.45M | $202.57M | $234.69M | $212.19M |
| Cost of revenue | $129.37M | $111.05M | $112.56M | $261.44M | $228.80M |
| Operating income | -$13.08M | -$23.21M | -$180.60M | -$667.65M | -$446.15M |
| EBITDA | $6.63M | -$27.64M | -$144.07M | -$398.20M | -$220.75M |
| Net income | -$21.02M | -$52.29M | -$175.77M | -$548.98M | -$245.39M |
| EPS (diluted) | $-0.73 | $-1.94 | $-7.23 | $-53.79 | $-74.91 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $523.71M | $419.38M | $418.76M | $490.94M | $554.09M |
| Total liabilities | $215.53M | $174.13M | $190.74M | $237.24M | $165.99M |
| Shareholders’ equity | $308.18M | $245.25M | $228.02M | $253.71M | $388.10M |
| Cash and equivalents | $105.00M | $85.21M | $99.68M | $123.93M | $400.57M |
| Long-term debt | $48.18M | $51.91M | $52.69M | $6.25M | $11.00M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $33.28M | -$28.50M | -$180.15M | -$319.15M | -$190.43M |
| Capital expenditure | -$19.02M | -$5.49M | -$5.71M | -$14.32M | -$20.79M |
| Free cash flow | $14.26M | -$33.99M | -$185.86M | -$333.48M | -$211.22M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | WGS | $69.46 | +2.6% | 26.03K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |